<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5919">
  <stage>Registered</stage>
  <submitdate>4/06/2016</submitdate>
  <approvaldate>4/06/2016</approvaldate>
  <nctid>NCT02795182</nctid>
  <trial_identification>
    <studytitle>BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies</studytitle>
    <scientifictitle>A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BGB-3111_BGB-A317_Study_001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <healthcondition>Leukemia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BGB-3111
Treatment: drugs - BGB-A317

Experimental: BGB-3111 and BGB-A317 - In the dose -escalation part, the dose levels and regimens will be evaluated.


Treatment: drugs: BGB-3111


Treatment: drugs: BGB-A317


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>From first dose to 28 days after last dose of BGB-3111 or BGB-A317</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to the time of the last measureable concentration (AUClast)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to infinity time (AUC0-infinity)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration (Cmax)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal elimination half-life (t1/2)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BTK inhibition activity of BGB-3111 by measurement of free BTK</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor response</outcome>
      <timepoint>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Aged = 18 years, able and willing to provide written informed consent and to comply
             with the study protocol.

          -  Laboratory parameters as specified below:

               -  Hematologic: platelet count &gt; 50 x 10e9/L; absolute neutrophil count &gt; 1.0 x109
                  cells/L;

               -  Hepatic: total Bilirubin = 1.5 times the upper limit of normal (ULN) ; and
                  aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) = 3x ULN

               -  Renal: creatinine clearance = 30 mL/min ; subjects requiring hemodialysis will be
                  excluded.

          -  Anticipated survival of at least 4 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          -  Female subjects of childbearing potential and non-sterile males must practice at least
             one of the following methods of birth control with partner(s) throughout the study and
             for = 3 months after discontinuing study drugs: total abstinence from sexual
             intercourse, double-barrier contraception, intrauterine device or hormonal
             contraceptive initiated at least 3 months prior to first dose of study drugs.

          -  Male subjects must not donate sperm from initial study drug administration, until 180
             days after drug discontinuation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known, active, central nervous system lymphoma or leukemia

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura

          -  History of stroke or cerebral hemorrhage within 6 months of enrollment

          -  History of significant cardiovascular disease, defined as:

               -  Congestive heart failure greater than New York Heart Association (NYHA) class II
                  according to the NYHA functional classification

               -  Unstable angina or myocardial infarction with 6 months of enrollment

          -  Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of
             breath, congestive obstructive pulmonary disease)

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

          -  Prior Bruton's tyrosine kinase (BTK) inhibitor or anti- programmed cell death-1
             (PD-1)/anti-Programmed Death Ligand-1 (PD-L1) treatment.

          -  History of interstitial lung disease or non-infectious pneumonitis except for those
             induced by radiation therapies

          -  Vaccination with a live vaccine within 28 days of the initiation of treatment.

          -  Participated in any investigational drug study within 28 days or not recovered from
             toxicity of any prior chemotherapy to grade = 1.

          -  Major surgery in the past 4 weeks

          -  Active and symptomatic fungal, bacterial and/or viral infection including evidence of
             infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus
             type 1 seropositive status

          -  Inability to comply with study procedures

          -  Pregnant or nursing women

          -  Men or women of childbearing potential who refuse to use an adequate measure of
             contraception unless they have past medical history of surgical sterilization.

          -  Any illness or condition that in the opinion of the investigator may affect safety of
             treatment or evaluation of any study's endpoints</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Concord Hospital - Sydney</hospital>
    <hospital>Monash Hospital - Clayton</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2139 - Sydney</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3002 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BeiGene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
      BGB-A317 in subjects with B-cell lymphoid malignancies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02795182</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eric Hedrick, MD</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@beigene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>